Pfizer, one of the world’s premier biopharmaceutical companies announces a state-of-the art R&D facility at Missouri, and the construction of the same is expected to be complete by mid-2019.
The new campus aims to bring together more than 450 of its employees who currently work at multiple locations and expects to hire an additional 80 employees over subsequent years to support research at the site.
The design features “flexible laboratory layouts, scientific casework and utility hookups, open office and collaboration spaces and increased conferencing technologies where researchers can collaborate,” said a press release by the firm.
The new headquarters is said to provide approximately 295,000 square feet of R&D space to house Pfizer’s BioTherapeutics Pharmaceutical Sciences group and enabling partners.
This team is responsible for advancement of Pfizer’s biologics, vaccines, and gene therapy portfolio by developing manufacturing processes and dosage forms application of state-of-the-art analytical technologies, conducting non-GMP manufacturing and scale-up studies.
“We’ve been proud to call Missouri home since 2002. During this time, we’ve benefitted from the excellent life sciences workforce based in Missouri, and also from a strong partnership with the State, St. Louis County, and the St. Louis Economic Development Partnership. All of these were important factors as we sought a new home where we could continue to evolve our business over the coming years.”
said John Ludwig, Senior Vice President of BioTherapeutics Pharmaceutical Sciences for Pfizer.The state and St. Louis County have also offered some incentives to keep Pfizer, in addition to a 10-year, 50% tax abatement on real and personal property, while Pfizer has said it will donate $20,000 to the local schools to support STEM (science, technology, engineering and mathematics) education.
